PMID- 38524631 OWN - NLM STAT- MEDLINE DCOM- 20240326 LR - 20240326 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 15 DP - 2024 TI - Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. PG - 1344376 LID - 10.3389/fendo.2024.1344376 [doi] LID - 1344376 AB - Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into the most common chronic liver disease globally, affecting 17-38% of the general population and 50-75% of patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum of chronic liver diseases, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH; or metabolic dysfunction-associated steatohepatitis, MASH) to fibrosis and cirrhosis with liver failure or/and hepatocellular carcinoma. Due to its increasing prevalence and associated morbidity and mortality, the disease-related and broader socioeconomic burden of NAFLD is substantial. Of note, currently there is no globally approved pharmacotherapy for NAFLD. Similar to NAFLD, osteoporosis constitutes also a silent disease, until an osteoporotic fracture occurs, which poses a markedly significant disease and socioeconomic burden. Increasing emerging data have recently highlighted links between NAFLD and osteoporosis, linking the pathogenesis of NAFLD with the process of bone remodeling. However, clinical studies are still limited demonstrating this associative relationship, while more evidence is needed towards discovering potential causative links. Since these two chronic diseases frequently co-exist, there are data suggesting that anti-osteoporosis treatments may affect NAFLD progression by impacting on its pathogenetic mechanisms. In the present review, we present on overview of the current understanding of the liver-bone cross talk and summarize the experimental and clinical evidence correlating NAFLD and osteoporosis, focusing on the possible effects of anti-osteoporotic drugs on NAFLD. CI - Copyright (c) 2024 Chondrogianni, Kyrou, Androutsakos, Flessa, Menenakos, Chatha, Aranan, Papavassiliou, Kassi and Randeva. FAU - Chondrogianni, Maria Eleni AU - Chondrogianni ME AD - Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. AD - Endocrine Unit, 1st Department of Propaupedic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kyrou, Ioannis AU - Kyrou I AD - Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, Athens, Greece. AD - Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Warwick Medical School, University of Warwick, Coventry, United Kingdom. AD - Centre for Health & Life Sciences, Coventry University, Coventry, United Kingdom. AD - Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom. AD - College of Health, Psychology and Social Care, University of Derby, Derby, United Kingdom. FAU - Androutsakos, Theodoros AU - Androutsakos T AD - Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Flessa, Christina-Maria AU - Flessa CM AD - Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Menenakos, Evangelos AU - Menenakos E AD - 5th Surgical Clinic, Department of Surgery, 'Evgenidion Hospital', National and Kapodistrian University of Athens Medical School, Athens, Greece. FAU - Chatha, Kamaljit Kaur AU - Chatha KK AD - Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Warwick Medical School, University of Warwick, Coventry, United Kingdom. AD - Department of Biochemistry and Immunology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. FAU - Aranan, Yekaterina AU - Aranan Y AD - Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. FAU - Papavassiliou, Athanasios G AU - Papavassiliou AG AD - Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kassi, Eva AU - Kassi E AD - Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. AD - Endocrine Unit, 1st Department of Propaupedic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Randeva, Harpal S AU - Randeva HS AD - Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom. AD - Warwick Medical School, University of Warwick, Coventry, United Kingdom. AD - Centre for Health & Life Sciences, Coventry University, Coventry, United Kingdom. LA - eng PT - Journal Article PT - Review DEP - 20240308 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM MH - Humans MH - *Non-alcoholic Fatty Liver Disease/drug therapy/epidemiology/etiology MH - *Diabetes Mellitus, Type 2/complications MH - Fibrosis MH - *Liver Neoplasms/complications MH - *Osteoporosis/drug therapy/epidemiology/etiology PMC - PMC10957571 OTO - NOTNLM OT - PTH OT - anti-osteoporotic drugs OT - bisphosphonates OT - calcitonin OT - denosumab OT - non-alcoholic fatty liver disease OT - romosozumab OT - selective estrogen receptor modulators COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2024/03/25 06:43 MHDA- 2024/03/26 06:44 PMCR- 2024/01/01 CRDT- 2024/03/25 04:28 PHST- 2023/11/25 00:00 [received] PHST- 2024/01/05 00:00 [accepted] PHST- 2024/03/26 06:44 [medline] PHST- 2024/03/25 06:43 [pubmed] PHST- 2024/03/25 04:28 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2024.1344376 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2024 Mar 8;15:1344376. doi: 10.3389/fendo.2024.1344376. eCollection 2024.